PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

Science Translational Medicine

Volumn 2, Issue 53, 2010, Pages

  Dedes, Konstantin J ^a   Wetterskog, Daniel ^a   Mendes Pereira, Ana M ^a   Natrajan, Rachael ^a   Lambros, Maryou B ^a   Geyer, Felipe C ^a   Vatcheva, Radost ^a   Savage, Kay ^a   Mackay, Alan ^a   Lord, Christopher J ^a   Ashworth, Alan ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KU 0058948; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51 PROTEIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; FLUOROBENZENE; KU0058948; PHTHALAZINE DERIVATIVE; PTEN PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL COMMUNICATION; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; DRUG TARGETING; ENDOMETRIOID ENDOMETRIUM CARCINOMA; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; IN VITRO STUDY; IRRADIATION; LOSS OF FUNCTION MUTATION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG ANTAGONISM; DRUG RESISTANCE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; FLUOROBENZENES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASES; PTEN PHOSPHOHYDROLASE;

EID: 77958049428     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001538     Document Type: Article

References (58)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M. J. Thun, Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. National Cancer Institute, Cancer Statistics 2009 [cited June 2010]; http://seer.cancer.gov/faststats.
3. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, I. Vergote, Endometrial cancer. Lancet 366, 491-505 (2005).
4. T. H. Dellinger, B. J. Monk, Systemic therapy for recurrent endometrial cancer: A review of North American trials. Expert Rev. Anticancer Ther. 9, 905-916 (2009).
5. G. F. Fleming, Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J. Clin. Oncol. 25, 2983-2990 (2007).
6. G. L. Mutter, M. C. Lin, J. T. Fitzgerald, J. B. Kum, J. P. Baak, J. A. Lees, L. P. Weng, C. Eng, Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 92, 924-930 (2000).
7. K. Kurose, X. P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, C. Eng, Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 158, 2097-2106 (2001).
8. L. Salmena, A. Carracedo, P. P. Pandolfi, Tenets of PTEN tumor suppression. Cell 133, 403-414 (2008).
9. D. Kong, A. Suzuki, T. T. Zou, A. Sakurada, L. W. Kemp, S. Wakatsuki, T. Yokoyama, H. Yamakawa, T. Furukawa, M. Sato,N. Ohuchi, S. Sato, J. Yin, S. Wang, J. M. Abraham, R. F. Souza, K. N. Smolinski, S. J. Meltzer, A. Horii, PTEN1 is frequently mutated in primary endometrial carcinomas. Nat. Genet. 17, 143-144 (1997).
10. H. B. Salvesen, N. MacDonald, A. Ryan, I. J. Jacobs, E. D. Lynch, L. A. Akslen, S. Das, PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91, 22-26 (2001).
11. M. Garofalo, G. Di Leva, G. Romano, G. Nuovo, S. S. Suh, A. Ngankeu, C. Taccioli, F. Pichiorri, H. Alder, P. Secchiero, P. Gasparini, A. Gonelli, S. Costinean, M. Acunzo, G. Condorelli, C. M. Croce, miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16, 498-509 (2009).
12. H. Yang, W. Kong, L.He, J. J. Zhao, J.D.O'Donnell, J.Wang, R. M.Wenham, D. Coppola, P. A. Kruk, S. V. Nicosia, J. Q. Cheng, MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433 (2008).
13. L. Poliseno, L. Salmena, J. Zhang, B. Carver, W. J. Haveman, P. P. Pandolfi, A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033-1038 (2010).
14. W. H. Shen, A. S. Balajee, J. Wang, H. Wu, C. Eng, P. P. Pandolfi, Y. Yin, Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157-170 (2007).
15. A. Gupta, Q. Yang, R. K. Pandita, C. R. Hunt, T. Xiang, S. Misri, S. Zeng, J. Pagan, J. Jeffery, J. Puc, R. Kumar, Z. Feng, S. N. Powell, A. Bhat, T. Yaguchi, R. Wadhwa, S. C. Kaul, R. Parsons, K. K. Khanna, T. K. Pandita, Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8, 2198-2210 (2009).
16. H. Farmer, N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, N. M. Martin, S. P. Jackson, G. C. Smith, A. Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
17. B. Evers, R. Drost, E. Schut, M. de Bruin, E. van der Burg, P. W. Derksen, H. Holstege, X. Liu, E. van Drunen, H. B. Beverloo, G. C. Smith, N. M. Martin, A. Lau, M. J. O'Connor, J. Jonkers, Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925 (2008).
18. C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, D. C. Ferguson, N. S. Ghoreishi-Haack, D. R. Grimm, R. Guan, E. K. Han, R. R.Holley-Shanks, B.Hristov, K. B. Idler, K. Jarvis, E. F. Johnson, L. R. Kleinberg, V. Klinghofer, L. M. Lasko, X. Liu, K. C.Marsh, T. P. McGonigal, J. A.Meulbroek, A. M. Olson, J. P. Palma, L. E. Rodriguez, Y. Shi, J. A. Stavropoulos, A. C. Tsurutani, G. D. Zhu, S. H. Rosenberg, V. L. Giranda,D. J. Frost, ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumormodels. Clin. Cancer Res. 13, 2728-2737 (2007).
19. N. McCabe, C. J. Lord, A. N. Tutt, N. M. Martin, G. C. Smith, A. Ashworth, BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency. Cancer Biol. Ther. 4, 934-936 (2005).
20. A. Ashworth, A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790 (2008).
21. P. C. Fong, D. S. Boss, T. A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M. J. O'Connor, A. Ashworth, J. Carmichael, S. B. Kaye, J. H. Schellens, J. S. de Bono, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
22. M. W. Audeh, J. Carmichael, R. T. Penson, M. Friedlander, B. Powell, K. M. Bell-McGuinn, C. Scott, J. N. Weitzel, A. Oaknin, N. Loman, K. Lu, R. K. Schmutzler, U. Matulonis, M. Wickens, A. Tutt, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376, 245-251 (2010).
23. A. Tutt, M. Robson, J. E. Garber, S. M. Domchek, M. W. Audeh, J. N. Weitzel, M. Friedlander, B. Arun, N. Loman, R. K. Schmutzler, A. Wardley, G. Mitchell, H. Earl, M. Wickens, J. Carmichael, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376, 235-244 (2010).
24. C. J. Lord, A. Ashworth, Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363-369 (2008).
25. M. Rouleau, A. Patel, M. J. Hendzel, S. H. Kaufmann, G. G. Poirier, PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301 (2010).
26. S. K. Sandhu, T. A. Yap, J. S. de Bono, Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. Eur. J. Cancer 46, 9-20 (2010).
27. B. McEllin, C. V. Camacho, B. Mukherjee, B. Hahm, N. Tomimatsu, R. M. Bachoo, S. Burma, PTEN loss compromises homologous recombination repair in astrocytes: Implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457-5464 (2010).
28. A. M. Mendes-Pereira, S. A. Martin, R. Brough, A. McCarthy, J. R. Taylor, J. S. Kim, T. Waldman, C. J. Lord, A. Ashworth, Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
29. + endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer 24, 207-212 (1999).
30. J. Pallares, E. Bussaglia, J. L. Martínez-Guitarte, X. Dolcet, D. Llobet, M. Rue, L. Sanchez-Verde, J. Palacios, J. Prat, X. Matias-Guiu, Immunohistochemical analysis of PTEN in endometrial carcinoma: A tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod. Pathol. 18, 719-727 (2005).
31. H. B. Salvesen, S. L. Carter, M. Mannelqvist, A. Dutt, G. Getz, I. M. Stefansson, M. B. Raeder, M. L. Sos, I. B. Engelsen, J. Trovik, E. Wik, H. Greulich, T. H. Bø, I. Jonassen, R. K. Thomas, T. Zander, L. A. Garraway, A. M. Oyan, W. R. Sellers, K. H. Kalland, M. Meyerson, L. A. Akslen, R. Beroukhim, Integrated genomic profiling of endometrial carcinoma associates aggressive tumorswith indicators of PI3 kinase activation. Proc.Natl. Acad. Sci. U.S.A. 106, 4834-4839 (2009).
32. P. J. Goodfellow, B. M. Buttin, T. J. Herzog, J. S. Rader, R. K. Gibb, E. Swisher, K. Look, K. C. Walls, M. Y. Fan, D. G. Mutch, Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc. Natl. Acad. Sci. U.S.A. 100, 5908-5913 (2003).
33. L. Catasus, A. Gallardo, M. Cuatrecasas, J. Prat, Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod. Pathol. 22, 522-529 (2009).
34. J. L. Hecht, G. L. Mutter, Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 24, 4783-4791 (2006).
35. J. I. Risinger, A. K. Hayes, A. Berchuck, J. C. Barrett, PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57, 4736-4738 (1997).
36. kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clin. Cancer Res. 15, 2456-2462 (2009).
37. S. L. Edwards, R. Brough, C. J. Lord, R. Natrajan, R. Vatcheva, D. A. Levine, J. Boyd, J. S. Reis-Filho, A. Ashworth, Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
38. J. J. Chen, D. Silver, S. Cantor, D. M. Livingston, R. Scully, BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59, 1752s-1756s (1999).
39. S. S. Yuan, S. Y. Lee, G. Chen, M. Song, G. E. Tomlinson, E. Y. Lee, BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 59, 3547-3551 (1999).
40. P. Cairns, K. Okami, S. Halachmi, N. Halachmi, M. Esteller, J. G. Herman, J. Jen, W. B. Isaacs, G. S. Bova, D. Sidransky, Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997-5000 (1997).
41. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M. H. Wigler, R. Parsons, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997).
42. S. I. Wang, J. Puc, J. Li, J. N. Bruce, P. Cairns, D. Sidransky, R. Parsons, Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183-4186 (1997).
43. N. McCabe, N. C. Turner, C. J. Lord, K. Kluzek, A. Bialkowska, S. Swift, S. Giavara, M. J. O'Connor, A. N. Tutt, M. Z. Zdzienicka, G. C. Smith, A. Ashworth, Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006).
44. E. Mladenov, B. Anachkova, I. Tsaneva, Sub-nuclear localization of Rad51 in response to DNA damage. Genes Cells 11, 513-524 (2006).
45. O. S. Gildemeister, J. M. Sage, K. L. Knight, Cellular redistribution of Rad51 in response to DNA damage: Novel role for Rad51C. J. Biol. Chem. 284, 31945-31952 (2009).
46. A. Mukhopadhyay, A. Elattar, A. Cerbinskaite, S. J. Wilkinson, Y. Drew, S. Kyle, G. Los, Z. Hostomsky, R. J. Edmondson, N. J. Curtin, Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344-2351 (2010).
47. M. K. Graeser, A. McCarthy, C. J. Lord, K. Savage, M. Hills, J. Salter, N. Orr, M. Parton, I. E. Smith, J. Reis-Filho, M. Dowsett, A. Ashworth, N. Turner, A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 10.1158/1078-0432.CCR-10-1027 (2010).
48. S. Fister, A. R. Günthert, G. Emons, C. Gründker, Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res. 67, 1750-1756 (2007).
49. S. A. Faruqi, P. G. Satyaswaroop, V. A. LiVolsi, R. B. Deger, J. S. Noumoff, Establishment and characterization of a poorly differentiated lethal human endometrial carcinoma cell line (NOU-1) with karyotype 46,XX. Cancer Genet. Cytogenet. 138, 44-49 (2002).
50. D. S. Tan, M. B. Lambros, S. Rayter, R. Natrajan, R. Vatcheva, Q. Gao, C. Marchiò, F. C. Geyer, K. Savage, S. Parry, K. Fenwick, N. Tamber, A. Mackay, T. Dexter, C. Jameson, W. G. McCluggage, A. Williams, A. Graham, D. Faratian, M. El-Bahrawy, A. J. Paige, H. Gabra, M. E. Gore, M. Zvelebil, C. J. Lord, S. B. Kaye, A. Ashworth, J. S. Reis-Filho, PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin. Cancer Res. 15, 2269-2280 (2009).
51. R. Natrajan, M. B. Lambros, S. M. Rodríguez-Pinilla, G. Moreno-Bueno, D. S. Tan, C. Marchió, R. Vatcheva, S. Rayter, B. Mahler-Araujo, L. G. Fulford, D. Hungermann, A. Mackay, A. Grigoriadis, K. Fenwick, N. Tamber, D. Hardisson, A. Tutt, J. Palacios, C. J. Lord, H. Buerger, A. Ashworth, J. S. Reis-Filho, Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 15, 2711-2722 (2009).
52. S. E. Halford, E. J. Sawyer, M. B. Lambros, P. Gorman, N. D. Macdonald, I. C. Talbot, W. D. Foulkes, C. E. Gillett, D.M. Barnes, L. A. Akslen, K. Lee, I. J. Jacobs, A. M. Hanby, T. S. Ganesan, H. B. Salvesen, W. F. Bodmer, I. P. Tomlinson, R. R. Roylance, MSI-low, a real phenomenon which varies in frequency among cancer types. J. Pathol. 201, 389-394 (2003).
53. M. Nishida, The Ishikawa cells from birth to the present. Hum. Cell 15, 104-117 (2002).
54. D. L. Way, D. S. Grosso, J. R. Davis, E. A. Surwit, C. D. Christian, Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro 19, 147-158 (1983).
55. C. J. Dawe, W. G. Banfield, W. D. Morgan, M. S. Slatick, H. O. Curth, Growth in continuous culture, and in hamsters, of cells from a neoplasm associated with acanthosis nigricans. J. Natl. Cancer Inst. 33, 441-456 (1964).
56. K. Isaka, H. Nishi, Y. Sagawa, T. Nakada, Y. Osakabe, H. Serizawa, Y. Ebihara, M. Takayama, Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma. Cancer Genet. Cytogenet. 141, 20-25 (2003).
57. S. Aebi, B. Kurdi-Haidar, R. Gordon, B. Cenni, H. Zheng, D. Fink, R. D. Christen, C. R. Boland, M. Koi, R. Fishel, S. B. Howell, Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56, 3087-3090 (1996).
58. H. Kuramoto, S. Tamura, Y. Notake, Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 114, 1012-1019 (1972).